Clinical Trials Browser

INDUSTRY × fludarabine × Clear all

NCT02601313 2026-03-18

ZUMA-2

Phase 2 Completed

105 enrolled 33 charts 2 FDA

Lymphoma, Mantle-Cell

NCT06153251 2026-03-18

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT06500273 2026-03-18

ALPHA3

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07480928 2026-03-18

DUAL-NK-PDAC

Phase 1/2 Recruiting

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT07480941 2026-03-18

DUAL-CAR-NK-GB

Phase 1 Recruiting

Glioblastoma, Glioma

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT05624554 2026-03-16

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03591510 2026-03-13

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04923893 2026-03-13

CARTITUDE-5

Phase 3 Active not recruiting

Multiple Myeloma

NCT06577025 2026-03-13

aMMbition

Phase 2 Active not recruiting

Multiple Myeloma

NCT07149857 2026-03-13

CARTITUDE-10

Phase 2 Recruiting

Multiple Myeloma

NCT07284433 2026-03-12

QUADvance

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05993299 2026-03-11

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

7 enrolled 15 charts

Neoplasms

NCT07015242 2026-03-11

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Phase 2 Recruiting

Lymphoma

NCT05537766 2026-03-10

ZUMA-25

Phase 2 Terminated

19 enrolled 28 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

NCT07304154 2026-03-10

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Phase 1 Not yet recruiting

Multiple Sclerosis, Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06045806 2026-03-05

KarMMa-9

Phase 3 Active not recruiting

Multiple Myeloma

NCT04416984 2026-03-04

ALPHA2

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03939026 2026-03-02

ALPHA

Phase 1 Completed

Lymphoma, Lymphoma, Follicular, Recurrence

NCT05714345 2026-03-02

EXPAND

Phase 2 Terminated

2 enrolled 8 charts

Lymphoma, Recurrence

NCT03967223 2026-02-25

IGNYTE-ESO

Phase 2 Active not recruiting

Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT06626919 2026-02-25

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Phase 1 Recruiting

Autoimmune Diseases, Muscular Diseases, Myasthenia Gravis, Muscle Weakness, Autoimmune Diseases of the Nervous System, Neuromuscular Manifestations

NCT06703346 2026-02-25

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

Neoplasms

NCT05170828 2026-02-24

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Phase 1 Withdrawn

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05826535 2026-02-24

Study of LYL314 in Aggressive Large B-Cell Lymphoma

Phase 1/2 Recruiting

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

NCT04426669 2026-02-23

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Phase 1/2 Completed

Gastrointestinal

Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT05566223 2026-02-23

CheckCell-2

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT07174427 2026-02-18

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

Phase 3 Recruiting

Sarcoma, Synovial

NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT06220201 2026-02-10

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Phase 1 Recruiting

Multiple Sclerosis, Myasthenia Gravis

NCT04674813 2026-02-09

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma

NCT03182244 2026-02-06

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Phase 3 Active not recruiting

276 enrolled 41 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06193889 2026-01-30

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Phase 2/3 Recruiting

Autoimmune Diseases, Myasthenia Gravis

NCT03926624 2026-01-22

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Phase 3 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04230265 2026-01-22

Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05357027 2026-01-21

HPV16 E6 TCR T Cells for Cervical Carcinoma

Phase 1/2 Terminated

Uterine Cervical Neoplasms

NCT04240002 2026-01-05

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

9 enrolled 21 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03105336 2025-12-23

ZUMA-5

Phase 2 Completed

159 enrolled 27 charts 1 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06253663 2025-12-16

JKART-1

Phase 2 Active not recruiting

Recurrence, Lymphoma, Mantle-Cell

NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04629729 2025-12-11

FT819 in Subjects With B-cell Malignancies

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell

NCT06680752 2025-12-10

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Phase 1/2 Recruiting

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

NCT06241456 2025-12-09

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Phase 3 Completed

371 enrolled 36 charts 2 FDA

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06001788 2025-12-03

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05534620 2025-12-02

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03391466 2025-12-01

ZUMA-7

Phase 3 Completed

359 enrolled 27 charts 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT06285422 2025-11-28

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

Phase 1 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07246304 2025-11-24

TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC

Phase EARLY_PHASE1 Recruiting

Small Cell Lung Carcinoma

NCT04880434 2025-11-17

ZUMA-2

Phase 2 Completed

Lymphoma, Mantle-Cell